Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies said after the close of the market on Thursday that Medicare contractor Palmetto GBA has established coverage of its next-generation sequencing-based assay, ClonoSeq, for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.